Tempus AI (NASDAQ:TEM) Shares Up 5.2% - What's Next?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s share price traded up 5.2% during trading on Friday . The stock traded as high as $91.45 and last traded at $88.11. 13,619,652 shares traded hands during trading, an increase of 2% from the average session volume of 13,370,095 shares. The stock had previously closed at $83.75.

Wall Street Analysts Forecast Growth

TEM has been the topic of several recent research reports. Wolfe Research started coverage on Tempus AI in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price on the stock. Piper Sandler restated a "neutral" rating and issued a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. William Blair downgraded Tempus AI from an "outperform" rating to a "market perform" rating in a report on Wednesday, February 12th. TD Cowen reaffirmed a "buy" rating and set a $74.00 price objective (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Finally, Bank of America raised their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research note on Friday, December 13th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $58.55.

Tempus AI Price Performance

The company's 50 day moving average is $49.05 and its two-hundred day moving average is $51.26. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Buying and Selling at Tempus AI

In related news, major shareholder Bradley A. Keywell sold 265,000 shares of the company's stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $35.10, for a total value of $9,301,500.00. Following the sale, the insider now owns 15,218,365 shares of the company's stock, valued at $534,164,611.50. The trade was a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Eric P. Lefkofsky sold 80,003 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $85.78, for a total transaction of $6,862,657.34. Following the transaction, the chief executive officer now owns 5,049,460 shares of the company's stock, valued at approximately $433,142,678.80. This represents a 1.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,401,779 shares of company stock valued at $115,707,361 in the last quarter.

Institutional Investors Weigh In On Tempus AI

Several large investors have recently modified their holdings of TEM. First Horizon Advisors Inc. bought a new stake in Tempus AI in the third quarter valued at $30,000. Operose Advisors LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth about $25,000. Farther Finance Advisors LLC acquired a new stake in shares of Tempus AI during the fourth quarter worth approximately $34,000. Prestige Wealth Management Group LLC raised its stake in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after acquiring an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC acquired a new position in shares of Tempus AI in the 4th quarter worth approximately $49,000. 24.22% of the stock is currently owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.